Glycated albumin (GA) is more advantageous than hemoglobin A1c for evaluating the efficacy of sitagliptin in achieving glycemic control in patients with type 2 diabetes.

Abstract

OBJECTIVE:

The aim of this study was to compare the utility of hemoglobin A1c (HbA1c) and glycated albumin (GA) for evaluating the efficacy of the dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin, in patients with type 2 diabetes.

METHODS:

Sitagliptin (50 mg) was administered orally once daily in 67 outpatients with type 2 diabetes. Drug effectiveness was deemed present if the HbA1c or GA level decreased by 5% at week 4 and week 12 relative to the baseline value.

RESULTS:

The mean HbA1c level decreased from 8.1 ± 1.0% at baseline to 7.8 ± 0.9% at week 4 and 7.2 ± 0.8% at week 12. The mean GA level decreased from 25.0 ± 4.5% at baseline to 22.2 ± 3.8% at week 4 and 20.8 ± 3.5% at week 12. At week 4 and week 12, the drug was effective in 37.8% and 71.6% of the patients, respectively, when assessed based on changes in HbA1c, and in 83.6% and 97.0% of the patients, respectively, when assessed based on changes in GA.

CONCLUSION:

GA is superior to HbA1c for evaluating the efficacy of sitagliptin treatment in patients with type 2 diabetes.

• Authors: Kenji Shima, Machiko Komatsu, Yoshihiko Noma, Keiko Miya
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 53 Issue 8 Pg. 829-35 ( 2014) ISSN: 1349-7235 [Electronic] Japan
• PMID: 24739602 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Blood Glucose
• Dipeptidyl-Peptidase IV Inhibitors
• Glycated Hemoglobin A
• Glycation End Products, Advanced
• Hypoglycemic Agents
• Pyrazines
• Serum Albumin
• Triazoles
• Sitagliptin Phosphate
• Glycated Serum Albumin

Topics

• Adult
• Aged
• Aged, 80 and over
• Blood Glucose (drug effects)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)
• Female
• Glycated Hemoglobin (analysis)
• Glycation End Products, Advanced
• Humans
• Hypoglycemic Agents (therapeutic use)
• Male
• Middle Aged
• Pyrazines (therapeutic use)
• Serum Albumin (analysis)
• Sitagliptin Phosphate
• Triazoles (therapeutic use)
• Glycated Serum Albumin